Big pharma joins hunt for coronavirus vaccine as outbreak escalatesBig pharma has joined the hunt for a vaccine for the deadly coronavirus outbreak that is beginning to Share XBig pharma joins hunt for coronavirus vaccine as outbreak escalateshttps://pharmaphorum.com/news/big-pharma-joins-hunt-for-coronavirus-vaccine-as-outbreak-escalates/
GSK completes travel vaccine offload as revamp continuesGlaxoSmithKline’s last act of 2019 was the completion of its near-€1 billion deal to divest two vaccines to Share XGSK completes travel vaccine offload as revamp continueshttps://pharmaphorum.com/news/gsk-completes-travel-vaccine-offload-as-revamp-continues/
Merck claims first-ever FDA approval for an Ebola vaccineMerck & Co’s Ebola vaccine Ervebo has been cleared for marketing in the US, just weeks after getting Share XMerck claims first-ever FDA approval for an Ebola vaccinehttps://pharmaphorum.com/news/merck-claims-first-ever-fda-approval-for-an-ebola-vaccine/
Biofabri’s TB vaccine collaboration presses ahead with vaccine trialA collaboration between Biofabri, a non-profit organisation, and academics from South Africa are pressing ahead with clinical development Share XBiofabri’s TB vaccine collaboration presses ahead with vaccine trialhttps://pharmaphorum.com/news/biofabris-tb-vaccine-collaboration-presses-ahead-with-vaccine-trial/
Experts concerned over mixed results from Takeda’s dengue vaccineTakeda’s dengue vaccine has met its target of protection against the disease in children – but there are Share XExperts concerned over mixed results from Takeda’s dengue vaccinehttps://pharmaphorum.com/news/experts-concerned-over-mixed-results-from-takedas-dengue-vaccine/
GSK’s TB vaccine makes a big step forward towards licensingGlaxoSmithKline has spent 20 years trying to develop an improved vaccine for tuberculosis, and new data for its Share XGSK’s TB vaccine makes a big step forward towards licensinghttps://pharmaphorum.com/news/gsks-tb-vaccine-makes-a-big-step-forward-towards-licensing/
CHMP backs world’s first Ebola vaccine from MSD, NewLinkMerck & Co/MSD’s Ebola vaccine has been recommended for conditional approval by the EMA’s main advisory committee, teeing Share XCHMP backs world’s first Ebola vaccine from MSD, NewLinkhttps://pharmaphorum.com/news/chmp-backs-worlds-first-ebola-vaccine-from-msd-newlink/
Still too little progress on antibiotic resistance, says O’Neill report updateThe O’Neill report on antimicrobial resistance in 2016 generated headlines around the world warning that once-trivial infections may Share XStill too little progress on antibiotic resistance, says O’Neill report updatehttps://pharmaphorum.com/news/still-too-little-progress-on-antibiotic-resistance-says-oneill-report-update/
GSK exits Ebola vaccine R&D as J&J rival starts Uganda trialGlaxoSmithKline has licensed vaccines for Ebola to the US Sabin Vaccine Institute, just as a major trial of Share XGSK exits Ebola vaccine R&D as J&J rival starts Uganda trialhttps://pharmaphorum.com/news/gsk-exits-ebola-vaccine-rd-as-jj-rival-starts-uganda-trial/
